Boston Scientific Subsidiaries Barred From Selling Multiple Drug-Eluting Stent Lines In Germany
This article was originally published in The Gray Sheet
A German court had previously blocked Boston Scientific’s German subsidiary from selling drug-eluting stents affected by OrbusNeich’s patent suit; the new injunction closes a loophole, preventing any Boston Scientific subsidiary from selling the devices in Germany.
You may also be interested in...
Maquet acquires LAAx. OrbusNeich says it called the cops on Boston Scientific. More news
Two deputy commissioners depart FDA. NICE takes over U.K. program to encourage adoption of new medical technologies. More news.
Acoramidis, AstraZeneca/BridgeBio Pharma's investigational treatment for patients with transthyretin amyloid cardiomyopathy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.